TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts
TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the company continues expanding its molecular glue degrader platform and advancing programs aimed at difficult-to-drug disease targets. The company appointed Mohan Bala as Chief Operating Officer while also adding Maria Koehler and David Tuveson to its growing Scientific Advisory Board.
The appointments reflect TRIANA’s efforts to strengthen both its executive leadership team and scientific advisory capabilities as the company advances its target-first and proximity-first molecular glue discovery platform into later stages of development. The biotechnology company has been focused on creating therapies capable of selectively degrading disease-driving proteins that have historically been difficult or impossible to target using conventional drug development approaches.
Molecular glue degraders have emerged as one of the most promising areas within precision medicine and targeted protein degradation research. Unlike traditional small molecule inhibitors, which typically block the activity of disease-related proteins, molecular glues are designed to bring proteins into proximity with cellular degradation machinery, triggering selective destruction of disease-causing targets.
This strategy has generated significant industry interest because it may allow researchers to address proteins previously considered “undruggable,” including transcription factors, scaffolding proteins, and other intracellular targets lacking conventional binding pockets. TRIANA has positioned itself within this rapidly growing field by focusing on proximity-driven molecular interactions intended to create highly selective degradation therapies.
The addition of Dr. Bala as Chief Operating Officer brings more than three decades of pharmaceutical and biotechnology industry experience to TRIANA at a time when the company is seeking to accelerate pipeline advancement and organizational growth.
According to TRIANA President and Chief Executive Officer Patrick Trojer, Bala’s experience across drug development, product strategy, commercialization planning, and market access makes him an important addition to the company’s leadership team as it advances its molecular glue degrader programs.
Trojer noted that Bala’s background spans both large pharmaceutical organizations and smaller biotechnology companies, giving him broad expertise across the entire therapeutic development continuum. He emphasized that TRIANA continues pushing the boundaries of molecular glue therapeutics and believes the company’s expanding scientific and operational leadership will help support the future growth of its pipeline.
Dr. Bala joins TRIANA with an extensive track record in oncology product development and strategic corporate operations. Over the course of his career, he has been closely involved in the global launch of seven oncology therapies, providing him with direct experience in bringing cancer medicines from clinical development through commercialization.
Before joining TRIANA, Bala served as Chief Development Officer at Mersana Therapeutics, where he played a central role in development strategy and business development activities. His work at Mersana contributed to strategic initiatives that ultimately culminated in the company’s acquisition by Day One Biopharmaceuticals.
Prior to Mersana, Bala held the position of Chief Operating Officer at Constellation Pharmaceuticals. During his tenure there, he oversaw multiple development functions and also contributed to the strategic business activities that led to Constellation’s acquisition by MorphoSys.
His broader career includes leadership positions at several major pharmaceutical and biotechnology organizations, including TESARO, Sanofi, GlaxoSmithKline, Centocor, and the Research Triangle Institute.
Bala earned a doctorate in Management Science from the University of Chicago, combining scientific and operational expertise that TRIANA believes will support the company’s transition into more advanced stages of clinical and commercial development.
Commenting on his appointment, Bala said he was attracted to TRIANA by the strength of its molecular glue technology platform, the experience of its leadership team, and the opportunity to help advance therapies targeting diseases with significant unmet medical need.
He specifically highlighted enthusiasm surrounding TRI-611, one of the company’s emerging pipeline candidates being developed for ALK-positive non-small cell lung cancer. According to Bala, the potential of the program and the broader pipeline make this an exciting period for TRIANA as it seeks to move additional therapeutic candidates into clinical development.
Alongside the executive appointment, TRIANA also expanded its Scientific Advisory Board with the addition of two highly recognized leaders in oncology research and drug development.
Dr. Maria Koehler brings extensive expertise in both academic medicine and pharmaceutical oncology development. A board-certified hematologist-oncologist, Koehler has more than twenty years of experience spanning bone marrow transplantation, cancer drug development, and biotechnology strategy.
She currently serves as a Partner at Omega Funds and as a senior advisor to Viking Global Investors. Her industry experience includes leadership roles across multiple major biotechnology and pharmaceutical organizations.
Koehler currently serves on the boards of Remix Therapeutics, Orum Therapeutics, and Abdera Therapeutics.
Previously, she served as Chief Medical Officer and Executive Vice President at Repare Therapeutics, where she helped guide synthetic lethality-based oncology development programs. She also held the role of Chief Medical Officer at Bicycle Therapeutics and served as Vice President of Strategy and Innovation at Pfizer Oncology.
Her earlier career included senior oncology leadership positions at AstraZeneca, GlaxoSmithKline, and Pfizer.
Koehler earned both her medical and doctoral degrees from the Silesian School of Medicine in Poland.
The second new advisory board appointment, Dr. David Tuveson, is widely regarded as one of the world’s leading translational oncology researchers, particularly in pancreatic cancer biology and tumor microenvironment research.
Tuveson currently serves as Director of the Cold Spring Harbor Laboratory Cancer Center and holds the title of Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory. He also serves as Chief Scientist for the Lustgarten Foundation for Pancreatic Cancer Research.
Throughout his career, Tuveson has held academic appointments at both the University of Pennsylvania and the University of Cambridge. His scientific work has contributed significantly to understanding pancreatic cancer progression, tumor biology, and translational therapeutic development.
Tuveson is also a past president of the American Association for Cancer Research and has been elected to both the National Academy of Medicine and the American Academy of Arts and Sciences.
He earned his medical and doctoral degrees from the Johns Hopkins University School of Medicine and completed additional clinical and fellowship training at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute.
TRIANA’s expansion of both its operational leadership and scientific advisory network comes during a period of growing investment and scientific interest in targeted protein degradation technologies. Molecular glue therapeutics have increasingly attracted attention from pharmaceutical companies and investors because of their potential to address disease mechanisms beyond the reach of traditional small molecules or antibody-based therapies.
The field has seen rapid advancement in recent years as researchers improve understanding of how induced protein-protein interactions can selectively eliminate disease-driving proteins. Several biotechnology companies are now pursuing molecular glue platforms across oncology, immunology, and neurodegenerative disease indications.
By strengthening its executive leadership and bringing in highly experienced oncology advisors, TRIANA appears focused on positioning itself competitively within this emerging therapeutic landscape. The company’s leadership believes its target-first and proximity-first discovery strategy may help unlock new opportunities for treating cancers and other diseases driven by challenging intracellular targets.
As TRIANA continues advancing programs such as TRI-611 and broader molecular glue degrader candidates, the addition of experienced industry operators and globally recognized scientific advisors may help accelerate development efforts while strengthening the company’s long-term strategic direction in precision oncology and targeted protein degradation research.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology.
TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
